

**SUPPLEMENTARY TABLES**

**Supplementary Table 1. MiRNAs that have potential binding sites with hsa\_circ\_0006014 predicted by circular RNA interactome, ENCORI, miRanda, and RNA hybrid databases.**

	<b>Circular RNA Interactome</b>	<b>StarBase</b>	<b>MiRanda</b>	<b>RNA hybrid</b>
miR-1236	√			
miR-1238	√			
miR-1247-5p	√		√	√
miR-1251-5p	√		√	√
miR-1304-5p	√		√	
miR-139-5p	√	√		√
miR-142-5p	√			
miR-149-5p	√			√
miR-182-5p	√	√	√	
miR-186-5p	√	√	√	
miR-409-3p	√		√	
miR-485-3p	√			
miR-488	√			
miR-545-3p	√		√	
miR-548p	√		√	
miR-571	√		√	
miR-572	√		√	
miR-616-3p	√		√	√
miR-651	√			
miR-671-5p	√			
miR-766-3p	√		√	√
miR-885-3p	√		√	√
miR-934	√			√
miR-940	√		√	

**Supplementary Table 2. The biological functions of the 8 miRNAs which coincidentally predicted in three out of four databases and half of them have clear evidence that they can suppress cancer.**

	<b>The total article associated with cancer (update to 202110114)</b>	<b>Tumor Promoter</b>	<b>Evidence</b>	<b>Tumor Suppressor</b>	<b>Evidence</b>
miR-1247-5p	8	+	PMID: <a href="#">25731699</a> ;	+	PMID: <a href="#">30249392</a> ; PMID: <a href="#">30175411</a> ; PMID: <a href="#">28586038</a> ; PMID: <a href="#">30967263</a> ;
miR-1251-5p	2	+	PMID: <a href="#">31278033</a> ; PMID: <a href="#">31918285</a>	-	
miR-139-5p	192	+	PMID: <a href="#">29516499</a> ;	+	PMID: <a href="#">29335523</a> ; PMID: <a href="#">29618950</a> ; PMID: <a href="#">31571923</a> ; PMID: <a href="#">29673587</a> ; PMID: <a href="#">30710422</a> ;etc.
miR-182-5p	128	+	PMID: <a href="#">29361949</a> ; PMID: <a href="#">30205384</a> ; PMID: <a href="#">30285878</a> ; PMID: <a href="#">30666836</a> ;etc.	+	PMID: <a href="#">30037856</a> ; PMID: <a href="#">30285878</a> ;
miR-186-5p	56	+	PMID: <a href="#">30981721</a> ;	+	PMID: <a href="#">30443183</a> ; PMID: <a href="#">30897321</a> ; PMID: <a href="#">29325758</a> ; PMID: <a href="#">30662805</a> ;etc.
miR-616-3p	3	+	PMID: <a href="#">29777710</a>	-	
miR-766-3p	12	-		+	PMID: <a href="#">30145863</a> ; PMID: <a href="#">28657135</a> ; PMID: <a href="#">31330234</a> ;
miR-885-3p	11	-		+	PMID: <a href="#">30784279</a> ; PMID: <a href="#">24882581</a> ;etc.

**Supplementary Table 3. Nine mRNAs marked red were candidates from the four middle coincident areas which were proved to promote the progression of cancer from published articles.**

20 common elements in "targetscan766", "targetscan885", "mirdb766" and "mirdb885":	9 common elements in "targetscan885" and "mirdb766":	1 common element in "targetscan885", "mirdb766" and "mirdb885":
VAPB	FBLN1	NTRK2
SLC8B1	FAM120C	
SH3PXD2A	DSG1	
ASTN1	RNASEL	
ZNF783	UBR2	
ERC1	PGM3	
AMOTL1	TRIM35	
PAN3	ASPHD2	
TSHZ2	PIAS2	
SLC12A5		
FAM126B		
BTBD9		
KDM3B		
SCMH1		
CDK6		
ZHX3		
SMIM12		
GGCX		
SPATS2L		
CELF3		

**Supplementary Table 4. Sequences for transient transfection RNAs and primers for circular RNA, micro RNAs, and mRNAs.**

Name		Sequence (5'–3')
siRNA-hsa_circ_0006014-1	Sense	CAAUGACAGUACUCGGGUUTT
	Antisense	AACCCGAGUACUGUCAUUGTT
siRNA-hsa_circ_0006014-2	Sense	ACAGUACUCGGGUUUCAUATT
	Antisense	UAUGAAACCCGAGUACUGUTT
siRNA-hsa_circ_0006014-3	Sense	CCAAUGACAGUACUCGGGUTT
	Antisense	ACCCGAGUACUGUCAUUGGTT
siRNA-NC	Sense	UUCUCCGAACGUGUCACGUTT
	Antisense	ACGUGAACGUUCGGAGAATT
mimics of miR-885-3p	Sense	AGGCAGCGGGGUGUAAGUGGAUA
	Antisense	UCCACUACACCCCGCUGCCUUU
mimics of NC	Sense	UCACAACCUCCUAGAAAGAGUAGA
	Antisense	UACUCUUUCUAGGAGGUUGUGAUU
inhibitor of miR-885-3p		UAUCCACUACACCCCGCUGCCU
		UCUACUCUUUCUAGGAGGUUGUGA
18S	Forward	CAGCCACCCGAGATTGAGCA
	Reverse	TAGTAGCGACGGGCGGTGTG
hsa_circ_0006014	Forward	AAGAGCGGATGAGGATACAG
	Reverse	AACAGCAAAATATGAAACCC
U6	RT	AAAAATATGGAACGCTCACGAATTTG
	Forward	GTGCTCGCTTCGGCAGCACATATAC
miR-139-5p	Reverse	AAAAATATGGAACGCTCACGAATTTG
	Forward	CTCTGCTCTACAGTGCACGTGTC
miR-186-5p	Reverse	TATGGTTGTTCTCGACTCCTTCAC
	Forward	CTCCAACGCAAAGAATTCTCC
miR-766-3p	Reverse	TATGCTTGTCTCGTCTCTGTGTC
	Forward	AATACTACTCCAGCCCCACAGC
miR-885-3p	Reverse	ATTCCATGTTGTCCACAGTCTCC
	Forward	CAGTAGGCAGCGGGGTGTAG
$\beta$ -ACTIN	Reverse	TATGCTTGTCTCGTCTCTGTGTC
	Forward	CCTCGCCTTTGCCGATCC
NTRK2	Reverse	GGATCTTCATGAGGTAGTCAGTC
	Forward	GCAATCCATTTACATGCTCCTGT
UBR2	Reverse	CATATTAGGAACCGGATCACCTG
	Forward	GTACCAGCATTTAGCCCACTATG
PGM3	Reverse	TGCAAGAATATGTAGGCTCTCCT
	Forward	GCAGAGAGTGCTTATTGACATCA
SH3PXD2A	Reverse	TGTGAAAGTTTCTCACTGCTGG
	Forward	AGACTATCTACCGGAGGTACAGC
ASTN1	Reverse	GCCACCTTCAATGGGAAACTT
	Forward	ACGACCTGAGCATCATGCAC
AMOTL1	Reverse	CACCACGACCATTTCTCCCG
	Forward	GAAACATCTGCTTTGACGGTGG
SLC12A5	Reverse	GAAGTTTGGGGAGTGGAAGTTAC
	Forward	GCCACCATGCTAAACAACCTG
	Reverse	GGTTCTCAGGAGTAGATGGTGAT

KDM3B	Forward	GCTTCGGTTCCTGTCAGATG
	Reverse	GACCTCGGCTGAATATCTCTTG
SPATS2L	Forward	CAACGCTGCACCGTTTCTCTA
	Reverse	GACGAGCAGTCAGGATTTCCA

**Supplementary Table 5. Details for primary and secondary antibodies.**

Name	Dilution Ratio	Company
TrkB	1:500	Abcam, Cambridge, UK
PIK3CA	1:2000	Abcam, Cambridge, UK
pan-AKT	1:500	Abcam, Cambridge, UK
pan-AKT (T308)	1:500	Abcam, Cambridge, UK
CDK2	1:500	Bioworld, Minnesota, USA
Cyclin E1	1:1000	CST, Massachusetts, USA
CDK4	1:1000	CST, Massachusetts, USA
CDK6	1:50000	Abcam, Cambridge, UK
Cyclin D1	1:10000	Abcam, Cambridge, UK
PCNA	1:1000	Abclonal, WuHan, China
$\beta$ -actin	1:1000	Santa Cruz Biotechnology, CA, USA
Anti-rabbit secondary fluorescent antibody	1:1000	Santa Cruz Biotechnology, CA, USA
Anti-mouse secondary fluorescent antibody	1:1000	Santa Cruz Biotechnology, CA, USA